PT-141 Providers, Compared on Price and Pharmacy Transparency
12 providers, each read directly off its own site — 1 publish no price for PT-141 at all, and only 6 name their pharmacy and state a regulatory category on the PT-141 page itself.
On this page▾
/ The board
Any paid placement here is marked Partner and listed first, as a disclosed commercial position — within that group, and separately within every other row, every provider is still ranked on the criteria printed on this page, never anything else (see disclosure). Full write-ups below.
“Flat price” means one all-in monthly figure with no separate membership or lab fee; any other pricing chip names the mechanic that gets in the way, or that the provider has not stated one. “Labs” is whether bloodwork is required, optional, not used, or not stated on the provider's own site. The pharmacy chip states a facility type (503A pharmacy, 503B facility, or 503A + 503B network where a company names pharmacies in both categories) only where the provider publishes one we could cite; “Not disclosed” means we read their site and they do not say, and “Unverified” means nobody has checked this company's pharmacy sourcing yet — of the 12 providers listed, 6 publish a facility type at all. Every provider here includes the clinician consult. Each row above shows the exact date its price was checked on that provider's own site — prices can change without notice.
Every provider read live off its own site by August 2026, ranked by the same criteria as the board above: pharmacy disclosure first, then advertised price, low to high. #1 is our top pick on those criteria — filter to see the rest a different way.
Showing our top 10 of 12, by pharmacy disclosure then price
1
Synergy Rx
Synergy Rx prices PT-141 "starting at $275" — the identical figure as its own NAD+ and Glutathione listings — and names the same four pharmacy partners those boards already document, though neither "503A" nor "503B" appears anywhere on its own site.
Bodybuilding Health+ fronts PT-141 Injection with a "$129/mo first month" figure that steps up to $179/mo afterward — the same first-month-teaser pattern already documented on its tirzepatide and Glutathione rows, and names no pharmacy anywhere on the site.
Names FOUR pharmacies outright (Pharmacy Innovations, Sweetgrass Pharmacy & Compounding, Absolute Pharmacy, Striker Pharmacy) and states the category with them: "licensed 503A pharmacies, not 503B outsourcing facilities"
EOS Health markets PT-141 on a dedicated men's sexual-health page, "From $135.20/mo" through the same five named pharmacies and regulatory category its NAD+ and Glutathione rows already document sitewide, though not restated on the PT-141 page itself.
Names five pharmacy partners directly, by name and city, with a stated regulatory category — on its sitewide Clinical & Pharmacy Partners page, the most specific pharmacy disclosure of any provider here
YourHealthRx states, unhedged, exactly which federal regulatory category its compounding pharmacies fall under, and prices PT-141 "as low as $209/mo" — though no specific pharmacy is named for it.
RxPepsDirect names its compounding pharmacy (Optimal Balance Pharmacy) and states a regulatory category for it directly on the same page that states the price and prices PT-141 at $75 per 10mg, the lowest per-unit figure here.
Names a specific pharmacy, VialsRX, with a stated regulatory category on its other compound pages — and gives PT-141 a real product page of its own, though no price sits on it.
Names its dispensing pharmacy directly and holds a real, checkable LegitScript seal — but its "From $160" headline understates the true standing rate by $20/mo.
What determines a row's position is printed below, and nothing else moves it: a commercial relationship can earn a provider a disclosed, labeled placement, but it cannot change the criteria, the verified prices, or the drawbacks we print beside any row. The 3 factors below are what actually move a row up or down.
No price at all is the real finding
1 of the 12 providers here publish no price for PT-141 anywhere on their own site — not a low number, an absence, and we record it plainly as "Not published" rather than guessing at one. 8 more quote only a "starting at" or "as low as" floor, or a first-month figure that steps up later, with no full dose-tier breakdown of what a real order costs. Just a couple publish one flat, unhedged price.
Pharmacy sourcing, on the record or not
We only mark a provider's pharmacy chip with a regulatory facility category when its own site names the facility AND states that category — of the 12 providers here, 6 do. Several of the rest name specific pharmacies without ever tying them to "503A" or "503B" in the same sentence, or state a category sitewide without restating it on the PT-141 page itself — a real, checkable gap, not an oversight on our part.
How the order is set
Any paid placement is marked Partner and listed first, as a disclosed commercial position — see the disclosure below the board. Within that group, and separately within every other row, the same rule applies: sorted by whether the provider clears the pharmacy-disclosure bar above, then by their own advertised price, low to high, for rows that tie. A provider's placement within its own group is never for sale.
Before you compare prices: PT-141 (bremelanotide) is different from every other compound this site boards. Unlike NAD+ and Glutathione, it does have an FDA-approved drug product: Vyleesi (bremelanotide injection), NDA 210557, approved by FDA in 2019 and manufactured by Cosette Pharmaceuticals — confirmed live on DailyMed, August 2026. But Vyleesi's approval covers one narrow use: "treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)" — nothing broader. Every provider here sells generic, compounded PT-141, not Vyleesi itself, and several market it to men specifically or with no HSDD-specific framing at all — a different population and use than the one FDA actually reviewed. That is a materially different situation from this site's tirzepatide and semaglutide boards, where a compounded version is sold specifically because the FDA-approved brand is in shortage: no shortage is behind what's sold here. What we score here is how honestly and clearly each provider states its price and pharmacy sourcing — not whether compounded PT-141 is an appropriate choice for you. Talk to a licensed clinician about that part.
Only confirmed PT-141 sellers are ranked here. Looking for a related wellness compound instead? Our GHK-Cu comparison shares three providers with this roster (Bodybuilding Health+, RxPepsDirect, YourHealthRx) but is not the same list — a provider selling PT-141 does not necessarily sell GHK-Cu, and vice versa. Our NAD+ and Glutathione comparisons use the same pharmacy-first method against different longevity-compound rosters. Looking for a GLP-1 or growth-hormone-axis peptide instead? Our tirzepatide comparison and sermorelin comparison round out the rest — see each board's own roster for what it actually confirmed.
Nothing on this page is medical advice. The only FDA-approved bremelanotide product is Vyleesi, approved for a specific indication in premenopausal women; every product here is a compounded formulation sold under a pharmacy's general authority, not Vyleesi itself and not a medication FDA has reviewed for the safety or efficacy of the use these providers market it for. We read every price and sourcing claim on this page directly off each provider's own site by August 2026; providers change prices without telling us, so verify the current number before you buy. Ask a licensed clinician whether PT-141 fits your situation.
